Clinical study of detorubicin. EORTC Clinical Screening Group.
A phase II trial of detorubicin (DTR) has been conducted on 164 patients with solid tumors. Regressions greater than or equal to 50% were obtained in 23% of the breast carcinoma patients, in 17% of the head and neck carcinoma patients and melanoma patients, and in 6% of the uteri cervix carcinoma patients. DTR seems to be as toxic as adriamycin for bone marrow and heart, but might induce a little less alopecia.
D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D003630:Daunorubicin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004341:Drug Evaluation; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*
D000903:Antibiotics, Antineoplastic; C017218:detorubicin; D003630:Daunorubicin